Feasibility of Dose Spacing of IL-23 Inhibitors Among Patients With Psoriasis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Real-World Evidence on Dose Spacing of IL-23 Inhibitors in the Treatment of Psoriasis
Am J Clin Dermatol 2024 Sep 27;[EPub Ahead of Print], M Luz, T TorresFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.